艾美疫苗:目标价 11 港元,增长潜力大

和讯网
14 Feb

【2 月 14 日,复星财富控股发研报,首次覆盖艾美疫苗并给予“买入”评级,目标价 11 港元,较 2 月 12 日收盘价有 100%上涨空间。】艾美疫苗是中国疫苗行业领军企业,有全产业链布局及卓越研发、生产和商业化能力,构建了多元化产品矩阵,拥有五大创新疫苗技术平台、四大生产基地,实现八款疫苗产品商业化。其完善营销网络覆盖中国 31 个省份,向巴基斯坦、塔吉克斯坦等国出口,展现出强劲国际拓展潜力...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10